Omeros Corporation is a clinical-stage biopharmaceutical company based in Seattle, Washington. The company develops therapeutics that modulate inflammation and immune pathways, with a particular emphasis on the complement system. Its research targets rare and serious disorders across immunology, hematology, nephrology, and transplant-related complications.
Omeros’ pipeline includes inhibitors of key complement enzymes, notably MASP-2 and MASP-3, alongside small-molecule programs directed at G protein–coupled receptors. The company previously developed the ophthalmic drug Omidria (phenylephrine and ketorolac intraocular solution), for which it continues to receive royalties following a divestiture of commercialization rights. Omeros is publicly listed on Nasdaq under the ticker OMER.
Operating profit rose 5% in DKK, 10% at CER. Obesity care sales up 37%. FDA approved Wegovy® for MASH. Novo Nordisk to acquire Akero Therapeutics. Full-year sales growth forecast at 8-11% CER.
Zaltenibart, a MASP-3 inhibitor, targets rare blood and kidney disorders. Omeros receives up to $2.1 billion, plus royalties. Novo Nordisk plans global phase 3 trials.
